Articles from Cutera, Inc.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announces their partnership with the Adaptive Training Foundation (ATF), a non-profit organization that provides access and inclusion to individuals living with physical or traumatic impairments empowering them through exercise and community.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024.

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, and its Japanese subsidiary, Cutera KK, are pleased to announce a strategic partnership with L’Oréal Japan Co. to exclusively promote, market, sell and distribute select SkinCeuticals products to medical and physician-led clinics in Japan.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the second quarter ended June 30, 2024, after the market closes on Thursday, August 8, 2024.

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announces the release of important new acne survey data as part of June’s Acne Awareness Month. The findings highlight the impact of acne on individuals and emphasize the substantial role of novel treatments like AviClear®, the first FDA-cleared energy-based device for the long-term treatment of mild, moderate, and severe inflammatory acne, in improving quality of life.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will hold an investor webinar at 11 a.m. PDT on June 20, 2024, to present an overview of AviClear, the first FDA-cleared energy device for the long-term treatment of mild, moderate, and severe inflammatory acne. The webinar will include a review of clinical data, market opportunity, future clinical studies, and real-world user experience.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, granted a total of 44,500 non-qualified inducement stock options to six employees. These awards were approved by the Compensation Committee of Cutera’s Board of Directors.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2024.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024.

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announces the launch of xeo+, a pioneering laser and light-based multi-application platform built on a rich history of excellence in performance and innovation. The xeo+ offers providers updated features and newly redesigned handpieces that allow for faster treatment times, optimized ease of use and an improved treatment experience.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the fourth quarter and full-year ended December 31, 2023.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Thursday, March 21, 2024.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced the international limited commercial release of AviClear, the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear received an enthusiastic reception at this year’s International Master Course on Aging Science (IMCAS) conference in Paris, France, held February 1-3.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced certain preliminary, unaudited financial results for the year ended December 31, 2023. These results are unaudited, subject to the completion of the Company’s year-end financial reporting processes, reviews, audit, and potential adjustments that might result.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Stephana Patton, who joined Cutera on November 13, 2023, as the Chief Legal Officer will receive a grant of inducement awards. The inducement awards consisted of stock options to purchase 30,000 of common stock, restricted stock units (RSUs) settleable in 25,000 shares of common stock, and performance stock units (PSUs) settleable in 55,000 shares of common stock. These awards will be approved by the Compensation Committee of Cutera’s Board of Directors at its next regularly scheduled meeting.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on November 15, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules (the “Listing Rules”) due to the Company’s inability to timely file its Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”). The Notice has no immediate effect on the listing or trading of the Company’s securities. Pursuant to Listing Rule 5250(c)(1), the Company was required to file the Form 10-Q by November 9, 2023 (the “Due Date”). The Company previously reported its inability to file the Form 10-Q by the Due Date in a Form 12b-25 that the Company filed with the SEC on November 13, 2023.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Taylor Harris, Chief Executive Office, and Greg Barker, Vice President of Corporate FP&A and Investor Relations, will participate in Fireside Chats at the following upcoming investor conferences:

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today provided preliminary financial results for the third quarter ended September 30, 2023, as well as recent business updates. Some Company highlights:

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the third quarter of 2023 after the market close on Wednesday, November 8, 2023.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that on October 3, 2023 the Compensation Committee of Cutera’s Board of Directors approved the grant of inducement awards to Brent Hauser, who joined Cutera on October 2, 2023, as the President, International. The inducement awards consisted of restricted stock units (RSUs) settleable in 27,358 shares of common stock, and two grants of performance stock units (PSUs) settleable in 54,716 shares of common stock and 25,000 shares of common stock, respectively.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023.

CUTERA, INC. (Nasdaq: CUTR) a global leader in aesthetic and dermatology solutions, today announces the launch of Secret DUO, an innovative skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies. Each modality can be used individually or in combination to target a wide range of aesthetic indications.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that on August 17,2023 the Compensation Committee of Cutera’s Board of Directors approved the grant of inducement awards to Jeffrey Jones, who joined Cutera on August 28, 2023, as the Chief Operating Officer. The inducement awards consisted of stock options to purchase 31,256 of common stock, restricted stock units (RSUs) settleable in 12,306 shares of common stock, and performance stock units (PSUs) settleable in 24,612 shares of common stock.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Jeff Jones as Chief Operating Officer, effective August 28, 2023. This move underscores Cutera’s commitment to delivering world-class product quality, reliability, and service to customers.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2023.

CUTERA, INC. (“Cutera” or the “Company”) (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that Taylor Harris has been appointed Chief Executive Officer, effective August 7, 2023. Mr. Harris will succeed Sheila Hopkins, who has been serving as Interim Chief Executive Officer since April 2023. Mr. Harris and Ms. Hopkins will both continue serving as members of Cutera’s Board of Directors.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the second quarter of 2023 after the market close on Tuesday, August 8, 2023.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Sheila Hopkins, Interim Chief Executive Officer, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th at 9:00 a.m. ET.

CUTERA, INC. (Nasdaq: CUTR) a global leader in aesthetic and dermatology solutions, today announces a new U.S. Food and Drug Administration Clearance of AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. This is the first acne therapy to claim long term effectiveness for mild, moderate and severe acne.

CUTERA, INC. (Nasdaq: CUTR) a global leader in aesthetic and dermatology solutions, today celebrates the start of Acne Awareness Month and a year since the unveiling of AviClear, the first FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne. Engineered with all skin types in mind, the AviClear laser selectively targets and suppresses the sebaceous glands, eliminating acne at the source, providing a durable solution to acne.

CUTERA, INC. (“Cutera” or the “Company”) (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that it has cancelled the Special Meeting of Stockholders previously scheduled for June 9, 2023 (the “Special Meeting”). The cancellation of the Special Meeting follows the withdrawals by former Chairman of the Board of Directors J. Daniel Plants and former Chief Executive Officer David H. Mowry of their respective demands to hold a special meeting of stockholders.

CUTERA, INC. (“Cutera” or the “Company”) (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today commented on the termination of the proxy solicitation by Voce Capital Management LLC (“Voce Capital”) with respect to the Special Meeting of Stockholders, scheduled for June 9, 2023 (the “Special Meeting”).

CUTERA, INC. (“Cutera” or the “Company”) (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that it has entered into cooperation agreements (the “Agreements”) with two of its largest stockholders, Pura Vida Investments, LLC (“Pura Vida”) and RTW Investments, LP (“RTW”), which collectively own more than 15% of the Company’s outstanding shares. Pursuant to the Agreements, the Company will appoint Kevin J. Cameron, Taylor C. Harris, Nicholas S. Lewin and Keith J. Sullivan (the “New Independent Directors”) to the Board of Directors (the “Board”) following the Special Meeting of Stockholders (the “Special Meeting”) to be held on June 9, 2023. Mr. Harris will also serve as a special advisor and consultant to the Company.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2023.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter of 2023 after the market close on Tuesday, May 9, 2023.

The Special Committee of the Board of Directors (the “Special Committee”) of CUTERA, INC. (the “Company”) (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today issued an open letter to stockholders.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, is honored to announce that this year marks the monumental 25th anniversary for the company as an industry leader and innovator.

CUTERA, INC. (the “Company”) (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced it will hold a Special Meeting of Stockholders (“Special Meeting”) on June 9, 2023, at 9:00 am PT in or near Brisbane, California for the purpose of considering proposals offered by J. Daniel Plants and David Mowry to remove, without cause, five of the six directors who were independent at the time of receiving the notices (the “Targeted Directors”).

CUTERA, INC. (the “Company”) (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced significant changes to the Company’s executive leadership to focus on improving performance and results. The Board of Directors (the “Board”) has appointed Sheila A. Hopkins as Interim Chief Executive Officer (“CEO”) and Janet D. Widmann as Independent Chair of the Board, effective immediately. The Board’s search for a permanent CEO is underway.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that based on the Company’s April 7, 2023 filing of its Form 10-K for the period ended December 31, 2022 (“Form 10-K”), Nasdaq has determined that the Company is now in compliance with the periodic filing requirement of Nasdaq Listing Rule 5250(c)(1). As previously announced, the Company received a notification letter from the Nasdaq that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-K. The Company is now in compliance with all Nasdaq Listing Rules.

CUTERA, INC. (the “Company”) (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today acknowledged receipt of, and issued the following response to, a demand by J. Daniel Plants to call a special meeting of stockholders.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on March 21, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules (the “Listing Rules”) due to the Company’s inability to timely file its Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) with the Securities and Exchange Commission (“SEC”). The Notice has no immediate effect on the listing or trading of the Company’s securities. Pursuant to Listing Rule 5250(c)(1), the Company was required to file the Form 10-K by March 16, 2023 (the “Due Date”). The Company previously reported its inability to file the Form 10-K by the Due Date in a Form 12b-25 that the Company filed with the SEC on March 16, 2023.

CUTERA, INC. (Nasdaq: CUTR) a leading provider of aesthetic and dermatology solutions, is proud to reveal the refreshed truBody brand. This award-winning treatment pairs two clinically proven technologies for a customized, convenient, and complete approach to fat reduction and muscle toning with 15-minute treatment options.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the fourth quarter and full-year ended December 31, 2022.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the fourth quarter and full year of 2022 after the market close on Tuesday, February 28, 2023.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. These results are subject to the completion of the Company’s year-end financial reporting processes, reviews, and audit.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced the pricing of $100 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Cutera also granted the initial purchasers of the notes an option to purchase up to an additional $20 million aggregate principal amount of the notes. The sale of the notes is expected to close on December 12, 2022, subject to customary closing conditions.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Cutera also intends to grant the initial purchasers of the notes an option to purchase up to an additional $20 million aggregate principal amount of the notes.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today disclosed that it has provided a response to a recent FDA inquiry.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and Greg Barker, Vice President, Corporate FP&A, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference at 2:00 pm ET on Wednesday, November 30, 2022, at the Lotte New York Palace Hotel, New York, NY.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and J. Daniel Plants, Executive Chairperson, will participate in a fireside chat at the Stifel Healthcare Conference at 8:00 am ET on Tuesday, November 15, 2022, at the Lotte New York Palace Hotel, New York, NY.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and Greg Barker, Vice President, Corporate FP&A, will participate in a fireside chat at the Stephens Annual Investment Conference at 4:00 pm CT on Wednesday, November 16, 2022, at the Grand Hyatt Hotel, Nashville, TN.

Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announces that AviClear is now broadly available to physicians and practitioners treating patients throughout North America. AviClear is the first and only energy device to be both FDA cleared and Health Canada approved for the treatment of mild, moderate, and severe acne, with additional approval in Canada for acne scars.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2022.

Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that the 12-month clinical data related to AviClear, the first and only FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne, was presented at the Annual Fall Clinical Dermatology Conference, which took place October 20-23 in Las Vegas, Nevada.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the third quarter of 2022 after the market close on Thursday, November 3, 2022.

Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announces that over 1,000 AviClear laser treatments have been performed in the United States. AviClear is the first and only energy-based device to be FDA-cleared for the treatment of mild, moderate and severe acne. Additionally, AviClear recently received approval from Health Canada for the treatment of all severities of acne as well as the treatment of acne scars.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2022.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the second quarter after the market close on Thursday, August 4, 2022.

Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey released today. The survey was conducted on behalf of Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, including AviClear, the first and only FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne that is now being made available in a limited North American release.

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced the pricing of $210 million aggregate principal amount of 2.25% convertible senior notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) (the “Rule 144A Offering”) and a separate concurrent private placement under Section 4(a)(2) of the Act on economic terms substantially similar to the notes being offered in the Rule 144A Offering to certain entities affiliated with J. Daniel Plants, Cutera’s Executive Chairman. Cutera also granted the initial purchasers of the notes an option to purchase up to an additional $30 million aggregate principal amount of the notes. The sale of the notes is expected to close on May 27, 2022, subject to customary closing conditions.

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and in a separate concurrent private placement pursuant to Section 4(a)(2) under the Act. Cutera also intends to grant the initial purchasers of the notes an option to purchase up to an additional $30 million aggregate principal amount of the notes.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2022.

CUTERA, INC. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of dermatology solutions, today announced that clinical data related to AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne; was presented during the annual meeting of the American Society for Laser Medicine and Surgery (ASLMS) which took place from April 27-30 in San Diego, CA.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter of 2022 after the market close on Tuesday, May 10, 2022.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of dermatological solutions, and Synchrony (NYSESYF), a leading provider of consumer payment and financing solutions, today announce an exclusive partnership to expand patient financing options to dermatology practices across the United States. Cutera’s AviClear is the first and only device cleared by the FDA for the treatment of mild, moderate and severe acne. Dermatologists offering AviClear will have the option to accept Synchrony’s CareCredit credit card, providing the millions of acne sufferers who seek treatment annually with flexible financing options.

CUTERA, INC. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of dermatology solutions, today announced that the first patient outside of clinical trials was treated with AviClear, the only device cleared by the FDA for the treatment of mild, moderate, and severe acne.

CUTERA, INC. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of dermatology solutions, today announced the U.S. Food and Drug Administration’s 510(k) clearance of AviClear, the first and only energy-based device to receive this designation for the treatment of mild, moderate, and severe acne.

Cutera, Inc. (NASDAQCUTR) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today announced that Dave Mowry, Chief Executive Officer, will participate in the Aesthetic Device Industry Panel at the Maxim Virtual Growth Conference at 1:00 p.m. ET on Monday, March 28, 2022.

Cutera, Inc. (NASDAQCUTR) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today reported financial results for the fourth quarter and full-year ended December 31, 2021.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, today announced that it will report financial results for the fourth quarter and full year 2021 after the market close on Tuesday, February 22, 2022.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of energy-based aesthetic systems for practitioners worldwide, today announced that Janet Widmann and Juliane Park will join its Board of Directors, effective immediately.